Sign inCreate account

Report workspace tools

NCT07198633RECRUITINGanonymous

An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

Sponsor

Source record

Qilu Pharmaceutical Co., Ltd.

Phase

Source record

Phase 1/2

Modality

AI-normalized

small molecule

Target

AI-normalized

B7H3 (CD276) - a target for antibody-drug conjugates (ADCs) and PROTACs in advanced prostate cancer.

Indication / condition

AI-normalized

Advanced Prostate Cancer

Intervention

Source record

QLC5508, abiraterone acetate, enzalutamide, QLH12016

Source & freshness

Source record

NCT ID

NCT07198633

Original source

ClinicalTrials.gov

Source last updated

Jun 02, 2026

Ingested at

May 19, 2026

Internal sync

May 23, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT07198633

Title

An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

Sponsor

Qilu Pharmaceutical Co., Ltd.

Status

RECRUITING

Phase

Phase 1/2

Condition raw

Advanced Prostate Cancer

Condition normalized

Advanced Prostate Cancer

Modality raw

antibody-drug conjugate

Modality normalized

small molecule

Target raw

B7H3 (CD276) - a target for antibody-drug conjugates (ADCs) and PROTACs in advanced prostate cancer.

Target normalized

B7H3 (CD276) - a target for antibody-drug conjugates (ADCs) and PROTACs in advanced prostate cancer.

Interventions

QLC5508, abiraterone acetate, enzalutamide, QLH12016

Public preview

Source record

QLC5508 and QLH12016 are being evaluated in combination with established therapies (abiraterone and enzalutamide) for advanced prostate cancer, a significant market with unmet needs. The trial's dual-phase design allows for both safety and efficacy exploration, potentially positioning Qilu Pharmaceutical Co., Ltd. favorably against competitors in the prostate cancer treatment landscape. The study's focus on patients who have failed standard therapies may enhance the asset's appeal in a crowded market. Successful outcomes could lead to accelerated development timelines and increased investor interest, particularly given the rising prevalence of prostate cancer globally.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT07198633

Status

RECRUITING

Phase

Phase 1/2

Sponsor

Qilu Pharmaceutical Co., Ltd.

Executive brief

Investment-Ready Snapshot

QLC5508 and QLH12016 are being evaluated in combination with established therapies (abiraterone and enzalutamide) for advanced prostate cancer, a significant market with unmet needs. The trial's dual-phase design allows for both safety and efficacy exploration, potentially positioning Qilu Pharmaceutical Co., Ltd. favorably against competitors in the prostate cancer treatment landscape. The study's focus on patients who have failed standard therapies may enhance the asset's appeal in a crowded market. Successful outcomes could lead to accelerated development timelines and increased investor interest, particularly given the rising prevalence of prostate cancer globally.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 02, 2026
Internal syncMay 23, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07198633

Indication

Advanced Prostate Cancer

Modality

small molecule

Target

B7H3 (CD276) - a target for antibody-drug conjugates (ADCs) and PROTACs in advanced prostate cancer.

Intervention

QLC5508, abiraterone acetate, enzalutamide, QLH12016

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.